Market Cap 9.35M
Revenue (ttm) 2.00M
Net Income (ttm) -59.61M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -2,980.50%
Debt to Equity Ratio 0.00
Volume 12,700
Avg Vol 42,639
Day's Range N/A - N/A
Shares Out 1.66M
Stochastic %K 85%
Beta 1.22
Analysts Hold
Price Target $10.00

Company Profile

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and squamous cell carcinoma o...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 558 0708
Fax: 858 558 0709
Address:
11085 Torreyana Road, San Diego, United States
BiotechValues
BiotechValues Apr. 22 at 5:26 PM
$BCAB EpCAM not at ASCO, so I wonder where/when they will release the update. Unless slide was wrong, it sounded like 1H 2026. That would be the biggest catalyst by far (if more responses)
1 · Reply
JA1950
JA1950 Apr. 22 at 4:30 PM
$BCAB Want to know why the stock jumped a little on Monday? Based on Context Therapeutics poster release from 4/20, a sale of the royalty for the drug could fetch---in my opinion, NOT FINANCIAL ADVICE/DO YOUR OWN RESEARCH--conservatively, $10-15M today, and substantially more ($20-30M) if sold at non-distressed prices. Let's go with $10M. That's $5.8/sh in cash. For a stock that is trading at $5.50.
0 · Reply
JA1950
JA1950 Apr. 22 at 4:15 PM
$BCAB Big news: Context Therapeutics released poster on April 20 for CT-202. (See below.) In my opinion, this confirms IND milestone payment of $2M forthcoming. That is greater than $1/sh and should provide runway for Tungsten to run a proper auction on other assets. Might also explain why no use of SEPA for the last four weeks--that or they are in a blackout period owing to term sheet for Oz-V SPV, etc. This poster and yesterday's re Mec-V suggest BCAB has assets significantly worth more than $9M market cap.
0 · Reply
JA1950
JA1950 Apr. 22 at 1:46 PM
$BCAB ASCO accepted abstract. Published on May 21. Presentation June 1. Should be a big deal.
0 · Reply
gregwiseman
gregwiseman Apr. 22 at 12:01 PM
$BCAB why is the garbage collapsing no news .
0 · Reply
gregwiseman
gregwiseman Apr. 22 at 11:42 AM
$BCAB is the garbage bancrupt finally collapsed without news.
0 · Reply
HjalmarTheGreat
HjalmarTheGreat Apr. 21 at 5:00 PM
$BCAB if presenting at ASCO we will see a press release at the end of the week. Last year it came on April 24th, the year prior was on April 25th. But they also stated that they wouldn’t provide updates until something definitive happens. I’ll assume that might include conferences. Right now, to be sure, data sharing is very controlled and happening behind closed doors. Let’s see.
2 · Reply
HjalmarTheGreat
HjalmarTheGreat Apr. 21 at 4:42 PM
$BCAB 2026: We can add another patent and another patent application to the books.
0 · Reply
SpaceRunners
SpaceRunners Apr. 20 at 9:22 PM
0 · Reply
gregwiseman
gregwiseman Apr. 20 at 8:16 PM
$BCAB what is going on with this garbage, if for any miracle this goes to 8,5 i get out in breakeven and i won,t come back again , i dont want to hear about this garbage any more for the rest of my life , will be cancelled from my watchlist for ever . shit stock
0 · Reply
Latest News on BCAB
BioAtla Announces Share Consolidation

Mar 31, 2026, 4:06 PM EDT - 22 days ago

BioAtla Announces Share Consolidation


BioAtla Cuts 30% of Jobs in Restructuring Effort

Mar 27, 2025, 5:05 PM EDT - 1 year ago

BioAtla Cuts 30% of Jobs in Restructuring Effort


BiotechValues
BiotechValues Apr. 22 at 5:26 PM
$BCAB EpCAM not at ASCO, so I wonder where/when they will release the update. Unless slide was wrong, it sounded like 1H 2026. That would be the biggest catalyst by far (if more responses)
1 · Reply
JA1950
JA1950 Apr. 22 at 4:30 PM
$BCAB Want to know why the stock jumped a little on Monday? Based on Context Therapeutics poster release from 4/20, a sale of the royalty for the drug could fetch---in my opinion, NOT FINANCIAL ADVICE/DO YOUR OWN RESEARCH--conservatively, $10-15M today, and substantially more ($20-30M) if sold at non-distressed prices. Let's go with $10M. That's $5.8/sh in cash. For a stock that is trading at $5.50.
0 · Reply
JA1950
JA1950 Apr. 22 at 4:15 PM
$BCAB Big news: Context Therapeutics released poster on April 20 for CT-202. (See below.) In my opinion, this confirms IND milestone payment of $2M forthcoming. That is greater than $1/sh and should provide runway for Tungsten to run a proper auction on other assets. Might also explain why no use of SEPA for the last four weeks--that or they are in a blackout period owing to term sheet for Oz-V SPV, etc. This poster and yesterday's re Mec-V suggest BCAB has assets significantly worth more than $9M market cap.
0 · Reply
JA1950
JA1950 Apr. 22 at 1:46 PM
$BCAB ASCO accepted abstract. Published on May 21. Presentation June 1. Should be a big deal.
0 · Reply
gregwiseman
gregwiseman Apr. 22 at 12:01 PM
$BCAB why is the garbage collapsing no news .
0 · Reply
gregwiseman
gregwiseman Apr. 22 at 11:42 AM
$BCAB is the garbage bancrupt finally collapsed without news.
0 · Reply
HjalmarTheGreat
HjalmarTheGreat Apr. 21 at 5:00 PM
$BCAB if presenting at ASCO we will see a press release at the end of the week. Last year it came on April 24th, the year prior was on April 25th. But they also stated that they wouldn’t provide updates until something definitive happens. I’ll assume that might include conferences. Right now, to be sure, data sharing is very controlled and happening behind closed doors. Let’s see.
2 · Reply
HjalmarTheGreat
HjalmarTheGreat Apr. 21 at 4:42 PM
$BCAB 2026: We can add another patent and another patent application to the books.
0 · Reply
SpaceRunners
SpaceRunners Apr. 20 at 9:22 PM
0 · Reply
gregwiseman
gregwiseman Apr. 20 at 8:16 PM
$BCAB what is going on with this garbage, if for any miracle this goes to 8,5 i get out in breakeven and i won,t come back again , i dont want to hear about this garbage any more for the rest of my life , will be cancelled from my watchlist for ever . shit stock
0 · Reply
winners3628
winners3628 Apr. 20 at 5:28 PM
$BCAB Key 2026 ASCO Annual Meeting Abstract Dates: Abstract Titles Released: April 21, 2026, at 10:00 AM (ET).
2 · Reply
Misterx69
Misterx69 Apr. 20 at 5:10 PM
$BCAB It seems like a little followed title 🤔
0 · Reply
BiotechValues
BiotechValues Apr. 20 at 2:36 PM
$BCAB finally bought back in here. Figure at $8M market cap and only 1.7M shares outstanding if they release anything positive it could skyrocket. Updated EpCAM data release should still be on track for this quarter, per the slides...
0 · Reply
HjalmarTheGreat
HjalmarTheGreat Apr. 17 at 5:27 PM
$BCAB After today Bioatla will have traded for 10 over a dollar. Now we wait for SPV and shareholder equity news. It's coming. Worth noting too that in mid February, the status of one of the clinical trial (NCT04918186) is finally showing that the status changed from "Not yet recruiting" to "recruiting."
3 · Reply
winners18
winners18 Apr. 17 at 1:14 AM
$BCAB stro another adc co mc 480 millions
1 · Reply
HjalmarTheGreat
HjalmarTheGreat Apr. 16 at 9:05 PM
$BCAB Interesting trading activity today.
0 · Reply
dudereally
dudereally Apr. 16 at 5:29 PM
$BCAB bonuses for driving a company into the fucking ground Paying themselves hundreds of millions of dollars to fail Sure they might have some technology, but it’s not saving a lot of people’s lives right now How about we add up all these bonuses and start with shareholders that have been around here the longest If somebody’s donated more to this Show than me then let them have it, but I got a feeling I’d be on the list even if I got a five dollars in a fuck you, I’d be happy 
1 · Reply
whateverhappenedthere
whateverhappenedthere Apr. 16 at 12:41 AM
$BCAB when do the exec bonuses get paid? Hopefully the issue a PR on this amazing accomplishment for shareholders!
1 · Reply
HjalmarTheGreat
HjalmarTheGreat Apr. 15 at 9:47 PM
$BCAB It’s not easy being the lone Bioatla investor. It’s lonely. Alas. Empty. But I am a rock; an island standing stoically in a sea of rough waters painted blue. Crested waves of uncertainty. Alone I ride the perfect storm of despair and confusion, intermingled with a tiny vision of hope; the sighting of a sandy beach splayed across the open sea, beckoning me to safety. Deserted, there thee I remain, surviving with a stamina and foresight often wasted upon less honorable men. I scream in agony. “Oz-V,” I cry, my proclamation echoing through salty, sea water caverns…. And finally a voice whispers back and says…. “Hjalmar, you’re a bit of an asshole, but you were right! You’re always right. You’re doing just fine.”
1 · Reply
gregwiseman
gregwiseman Apr. 15 at 6:37 PM
$BCAB can someone expain how the fuck did they approved the reverse split since they didnt have wast majority of the shareholders to vote for reverse split . the scam company approved the reverse split without the vote of the shareholders.
1 · Reply
HjalmarTheGreat
HjalmarTheGreat Apr. 15 at 4:37 PM
$BCAB Anything can happen here. I've been looking at CSPC and it would be a great match for Bioatla from both a geographical and pipeline perspective. CSPC even mentions bioatla in patent US 20250345445 A1. CSPC has a similar asset to Oz-V, but I think in phase 1/2(?) Bioatla asset, phase 3 ready. It's complimentary science, and Himalaya is already there in Greater China. Without question, CSPC is scrutinizing ADC patents as they've been active in the patent courts of late, aggressively clearing the path for their own pipeline. Just a thought since we have never discussed that pharma giant. I'd be happy to see CSPC partner in some way with BCAB. Or, acquire it, please? :)
0 · Reply
gregwiseman
gregwiseman Apr. 15 at 8:16 AM
$BCAB the otc or bancruptcy news today. im sorry for the stockholders
1 · Reply